Search clinical trials for: Lineage-targeted risk and minimal residual disease

Total 481120 results

Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

MRD/Risk-oriented Therapy of Adult Ph- ALL Including Pegylated Asparaginase and Lineage-targeted Methotrexate (LAL1913)

Secondary | De Novo | Untreated Philadelphia Positive Acute Lymphoblastic Leukemia | Low-dose Corticosteroids Pretreatment

Italy
The First Affiliated Hospital of Soochow University

Not yet recruiting

Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection

Multiple Myeloma | Newly Diagnosed | MRD | High Risk
University of Oklahoma

Not yet recruiting

Relugolix + Enzalutamide Study in High-Risk Prostate Cancer

Androgen Deprivation Therapy | Locally Advanced Prostate Cancer

United States
University of Aarhus
Aarhus University Hospital

Recruiting

DANISH.MRD: Danish Assessment of Minimal Residual Disease by Liquid Biopsies (DANISH_MRD)

Colorectal Neoplasms | Colorectal Cancer | Colorectal Adenocarcinoma | Colorectal Cancer Stage II | Colorectal Cancer Stage III | Colorectal Cancer Stage I

Denmark
Peking University People's Hospital

Recruiting

Clinical Research of Drug Holiday Based on MRD Detection in GIST Patients at High Risk of Recurrence

Gastrointestinal Stromal Tumors

China
Peking University People's Hospital

Recruiting

Prediction of Postoperative Treatment Efficacy and Recurrence Risk of High-risk GIST Based on Liquid Biopsy MRD

Gastrointestinal Stromal Tumors | Minimal Residual Disease

China
Fang Wu
Zhejiang Cancer Hospital; Xiangya Hospital of Central South University; Sun Yat-sen... and other collaborators

Recruiting

ctDNA Analysis to Monitor the Risk of Progression After First-line Immunotherapy in Patients With Advanced NSCLC (CR1STAL)

Advanced Lung Non-Small Cell Carcinoma

China
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Secondary Acute Myeloid Leukemia | Myelodysplastic Syndrome | Minimal Residual Disease | Hematopoietic Cell Transplantation Recipient | Acute Myeloid Leukemia in Remission | Acute Lymphoblastic Leukemia in Remission

United States
University of Birmingham
Assistance Publique - Hôpitaux de Paris; Pfizer; Cancer Research UK; National Cancer...

Recruiting

International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia (Myechild01)

Acute Myeloid Leukaemia

France, Switzerland, United Kingdom, New Zealand, Australia, Ireland
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease

B Acute Lymphoblastic Leukemia | Philadelphia Chromosome Positive | Minimal Residual Disease | Adult Acute Lymphoblastic Leukemia in Complete Remission

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Stem Cell Transplant to Treat Patients With Favorable or Intermediate Risk Minimal Residual Disease Negative Acute Myeloid Leukemia

Acute Myeloid Leukemia | Minimal Residual Disease Negativity

United States
Amgen

Terminated

Effect of Blinatumomab on Minimal Residual Disease (MRD) in Diffuse Large B-Cell Lymphoma (DLBCL) Subjects Post Autologous Hematopoietic Stem Cell Transplantation (aHSCT)

High-risk Diffuse Large B-cell Lymphoma

United States, Italy, Belgium, Switzerland, Australia, France, Greece
Chinese PLA General Hospital

Unknown

Combined Inhibition of PD-1 and DNA Hypomethylating Agent +/- Chemotherapy in High-risk AML or Elderly Patients With AML Who Are Unfit for Intensive Chemotherapy

Acute Myeloid Leukemia, in Relapsed or Refractory | Acute Myeloid Leukemia, Elderly, Unfit | Acute Myeloid Leukemia With Positive Minimal Residual Disease

China
Nanfang Hospital of Southern Medical University
Peking University People's Hospital; Guangzhou First People's Hospital; Sun Yat-Sen... and other collaborators

Completed

MRD-directed Therapy for Low-risk and Intermediate-risk AML.

Acute Myeloid Leukemia | Minimal Residual Disease

China
Sellas Life Sciences Group

Unknown

WT1 Analog Peptide Vaccine in Patients With Multiple Myeloma Following Autologous Stem Cell Transplantation

Multiple Myeloma | Minimal Residual Disease | High-Risk Cancer

United States
PETHEMA Foundation

Completed

LAL-BR/2001: Study Treatment to Low Risk ALL

Acute Lymphoblastic Leukemia

Spain
Northern Italy Leukemia Group
Associazione Italiana per la Ricerca sul Cancro

Completed

Treatment of Adult ALL With an MRD-directed Programme.

Acute Lymphoblastic Leukemia

Italy
Johann Wolfgang Goethe University Hospital

Completed

Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab

Adult Acute Lymphocytic Leukemia

Germany
University of Bologna

Unknown

Adoptive Immunotherapy of High Risk Acute Myeloblastic Leukemia Patients Using Haploidentical Kir Ligand-mismatched Natural Killer Cells

Myeloblastic Leukemia

Italy
Zhujiang Hospital

Not yet recruiting

Compare the Accuracy of ctDNA-MRD and MVI Result in Predicting Postoperative Recurrence of Hepatocellular Carcinoma

Recurrence | Surgery | Hepatocellular Carcinoma Resectable

China
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

Predictive Determinants of Nephrotic Syndrome Remission in Patients With At-risk Polymorphism of APOL1 (NEPHROL1)

Focal Segmental Glomerulosclerosis | Nephrotic Syndrome | APOL1 Associated Kidney Disease

France
Sir Run Run Shaw Hospital

Not yet recruiting

A Study of SBRT Combined With Puterizumab in Intrapulmonary Metastasis From NSCLC

Non-Small-Cell Lung Cancer
Peter MacCallum Cancer Centre, Australia
AbbVie

Not yet recruiting

MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma (EpLCART)

Relapsed/Refractory Large B-cell Lymphoma

Australia
Fondazione Policlinico Universitario Agostino Gemelli...

Not yet recruiting

Minimally Invasive Simple Hysterectomy in Low Risk Cervical Cancer (LASH)

Cervical Cancer | Cervix Cancer
Exact Sciences Corporation
Labcorp Corporation of America Holdings, Inc

Recruiting

First CORRECT Study of Minimal Residual Disease (MRD) Detection in Colorectal Cancer (MRD)

Colorectal Cancer

United Kingdom, Spain, Italy, Israel
University Hospital, Brest

Not yet recruiting

Residual Pulmonary Vascular Obstruction Index Computed With Ventilation/Perfusion SPECT/CT Imaging to Predict the Risk of Venous Thromboembolism Recurrence in Patients With Pulmonary Embolism (PRONOSPECT) (PRONOSPECT)

Venous Thromboembolism | Pulmonary Embolism

France
AbbVie

Recruiting

A Study to Assess Frequency of Undetectable Minimal Residual Disease (uMRD) in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets ± Intravenously (IV) Infused Rituximab in Routine Clinical Practice in Japan

Chronic Lymphocytic Leukemia

Japan
M.D. Anderson Cancer Center
Bellicum Pharmaceuticals, Inc.

Not yet recruiting

Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

Colorectal Cancer | Minimal Residual Disease

United States
Nantes University Hospital
Janssen Pharmaceutica

Not yet recruiting

Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma (IFm2022-01)

Multiple Myeloma

France
Fudan University

Not yet recruiting

Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022)

Lung Cancer | Minimal Residual Disease | EGFR Gene Mutation
University Health Network, Toronto

Recruiting

Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma (ClearMe)

Cutaneous Melanoma | Mucosal Melanoma | Melanoma Stage IV

Canada
Institute of Hematology & Blood Diseases Hospital...

Recruiting

Detecting Minimal Residual Diseases (MRD) and Monitoring Clonal Evolution Using Ultrasensitive Chromosomal Aberrations Detection (UCAD) in Multiple Myeloma

Multiple Myeloma
Peking University People's Hospital
Ruijin Hospital; Wuhan TongJi Hospital; Anhui Provincial Hospital

Not yet recruiting

MRD Response-adapted Allo-HSCT for Adverse-risk AML

Acute Myeloid Leukemia
Odense University Hospital
Karolinska University Hospital

Not yet recruiting

The Efficacy of PIPAC and Minimally Invasive Radical Resection in High-risk Gastric Cancer Patients. (EPICURE)

Gastric Cancer | Peritoneal Metastases | Chemotherapy, Adjuvant | Minimally Invasive Surgical Procedures

United States, Sweden, Denmark, France, Germany
Federal Research Institute of Pediatric Hematology...
University Medical Center, Kazakhstan

Recruiting

Abdominal Neuroblastoma Laparoscopic Surgery Risk Factors Stratification (ANLAP-R)

Neuroblastoma | Ganglioneuroblastoma | Ganglioneuroma

Russian Federation
University Hospital, Montpellier

Not yet recruiting

French Assessment of MRD by Liquid Biopsies in Stage III CRC Patients (FRENCH.MRD.CRC)

Colorectal Cancer | Minimal Residual Disease | Liquid Biopsy | Stage III Colon Cancer
University Hospital, Montpellier

Not yet recruiting

French Assessment of MRD by Liquid Biopsies in Colorectal With Liver Metastasis Patients (FRENCH.MRD.CRLM)

Colorectal Cancer | Liver Metastases | Minimal Residual Disease | Liquid Biopsy | Stage IV Colorectal Cancer | ctDNA
University Hospital, Montpellier

Not yet recruiting

French Assessment of MRD by Liquid Biopsies in PDAC Patients (FRENCH.MRD.PDAC)

Pancreatic Ductal Adenocarcinoma | Pancreatic Cancer Resectable | Minimal Residual Disease | Liquid Biopsy | ctDNA
The First Hospital of Jilin University

Recruiting

Detection of Minimal Residual Disease in Resectable Stage II-IIIB Non-small Cell Lung Cancer

Lung Cancer

China
Gruppo Oncologico del Nord-Ovest

Recruiting

Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease (TRINITY)

Gastric Cancer | HER2-positive Gastric Cancer

Italy
Personalis Inc.

Recruiting

ctDNA Based MRD Testing for NAC Monitoring in TNBC (B-STRONGER-I)

Minimal Residual Disease | TNBC - Triple-Negative Breast Cancer

United States
Jiangsu Cancer Institute & Hospital

Recruiting

MRD-guided Prognosis Prediction and Adjuvant Treatment Based on CTC and ctDNA in NSCLC

Non-small Cell Lung Cancer

China
Institute of Hematology & Blood Diseases Hospital...

Recruiting

DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma

Multiple Myeloma

China
Qilu Hospital of Shandong University
The Affiliated Hospital of Qingdao University; Shandong Provincial Hospital; Jinan... and other collaborators

Recruiting

Minimal Residual Disease-guided Adjuvant Therapy for Gastric Cancer

Stage II-III Gastric Cancer

China
Fudan University
Shanghai Weihe Medical Laboratory Co., Ltd.

Not yet recruiting

Assessment of Early Pancreatic Cancer Prognosis by Minimal Residual Disease Using Multi-omics Approach

Pancreatic Ductal Adenocarcinoma

China
H. Lee Moffitt Cancer Center and Research Institute
Kite, A Gilead Company

Recruiting

Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Acute Lymphoblastic Leukemia | B-Cell Lymphoblastic Leukemia

United States
Zhejiang University

Recruiting

Prospective, Single-arm, Multicenter Clinical Study on Haploidentical Hematopoietic Stem Cell Transplantation in Patients With MRD Positive CD19+ALL Treated With Conditioning Regimens Containing Blinatumomab

Acute Lymphoblastic Leukemia

China
University Medical Center Groningen
Centre Hospitalier Universitaire de Nice; LungenClinic Grosshansdorf

Recruiting

Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Stage III NSCLC (MRD-LUNG)

Lung Cancer Stage III

France, Germany, Netherlands
Claus Lindbjerg Andersen
Karolinska Institutet; Medical University of Graz; University of Aarhus; Universitätsklinikum... and other collaborators

Recruiting

Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Colorectal Cancer

Colorectal Cancer Stage III | Liver Metastasis Colon Cancer

Germany, Denmark, Austria, France, Sweden
FengYan Jin

Not yet recruiting

A Perspective Study of the MRD-tailored Therapy in Patients With Newly Diagnosed Multiple Myeloma With Persistent Minimal Residual Disease After Initial Treatment (MRD)

Multiple Myeloma | Minimal Residual Disease

Search clinical trials for: Lineage-targeted risk and minimal residual disease

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Equatorial Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations